<DOC>
	<DOC>NCT00546715</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection</brief_summary>
	<brief_title>A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Key Chronically infected with hepatitis C virus genotype 1 Treatment naive or treatment nonresponders or treatment intolerant; and not coinfected with HIV or hepatitis B virus Hepatitis C virus RNA viral load of ≥ 10*5* IU/mL BMI 18 to 35 kg/m² Key Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with hepatitis C virus infection Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>